Scientific and practical aspects and prospects for the use of emolent+ LIPIKAR BAUME AP+MAX® (resolution of the council of experts)
https://doi.org/10.33667/2078-5631-2026-3-94-98
Abstract
On December 18, 2025, an expert consultation on «Practical Aspects and Prospects for the Use of the Emollient LIPIKAR BAUME AP+MAX®» was held in Moscow. This scientific event provided a platform for discussing the skin microbiome and its role in the pathogenesis of chronic skin diseases, particularly atopic dermatitis, taking into account current scientific data. The consultation also addressed the use of the new emollient+ LIPIKAR BAUME AP+MAX® in patient management algorithms for atopic dermatitis, based on current clinical protocols. The discussion focused on the mechanisms of itching in atopic dermatitis, as well as the relationship between xerosis and itching in light of the prospects for the use of emollients+. Data on the effectiveness of the new emollient+ LIPIKAR BAUME AP+MAX® in patients with atopic dermatitis were also discussed.
About the Authors
L. S. Kruglova
Central State Medical Academy of the Administrative Department of the President of the Russian
Federation
Russian Federation
Russian Federation
Kruglova Larisa S., Dr Med Sci (habil.), professor, head of Dept of Dermatovenereology and Cosmetology, rector
Moscow
E. A. Araviyskaya
Pavlov First State Medical University of St. Petersburg (Pavlov University) ; GALAKTIKA Beauty Institute
Russian Federation
Russian Federation
Araviyskaya Elena A., Dr Med Sci (habil.), pofessor at Dept of Dermatovenereology with a Clinic, head of the Postgraduate Training Course in Cosmetology for doctors, consultant
Saint Petersburg
A. N. Lvov
Central State Medical Academy of the Administrative Department of the President of the Russian
Federation ; Lomonosov Moscow State University
Russian Federation
Russian Federation
Lvov Andrey N., Dr Med Sci (habil.), head of Postgraduate and Residency Studies, professor at Dept of Dermatovenereology and Cosmetology, chief researcher
Moscow
N. N. Murashkin
Central State Medical Academy of the Administrative Department of the President of the Russian
Federation ; Scientific Center for Children’s Health
Russian Federation
Russian Federation
Murashkin Nikolai N., Dr Med Sci (habil.), professor, head of Dept of Dermatology with Laser Surgery Group, head of the Laboratory of Pediatric Skin Pathology, head of the Research Institute of Pediatric Dermatology, professor at Dept of Dermatovenereology and Cosmetology
Moscow
E. V. Sokolovsky
Pavlov First State Medical University of St. Petersburg (Pavlov University)
Russian Federation
Russian Federation
Sokolovsky Evgeny V., Dr Med Sci (habil.), professor, head of Dept of Dermatovenereology with a Clinic
Saint Petersburg
E. A. Shatokhina
Central State Medical Academy of the Administrative Department of the President of the Russian
Federation ; Lomonosov Moscow State University
Russian Federation
Russian Federation
Shatokhina Evgenia A., Dr Med Sci (habil.), professor at Dept of Dermatovenereology and Cosmetology, researcher
Moscow
References
1. Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier.Exp Dermatol 2008; 17: 1063–1072.
2. Luebberding S, Krueger N, Kerscher M. Age-related changes in skin barrier function – quantitative evaluation of 150 female subjects. Int J Cosmet Sci 2013; 35: 183–190.
3. Lambers H, Piessens S, Bloem A, Pronk H, Finkel P. Natural skin surface pH is on average below 5, which is beneficial for its resident flora. Int J Cosmet Sc 2006; 28: 359–370.
4. Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol. 2006; 19: 296–302.
5. Jurakić Tončić R, Marinović B. The Role of Impaired Epidermal Barrier Function in Atopic Dermatitis. Acta Dermatovenerol Croat. 2016; 24: 95–109.
6. Thawer-Esmail F. Skin barrier function and atopic eczema. Curr Allergy Clin Immunol 2011; 24: 1938.
7. Jurakic T.R., Sanja K., Ljubojevic H.S., Branka М. Skin Barrier and Dry Skin in the Mature Patient, Clinics in Dermatology (2017). DOI: 10.1016/j.clindermatol.2017.10.002
8. De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol 2009; 129: 14–30.
9. Ladd M, Sharma A, Huang Q, Wang AY, Xu L, Genowati I, et al. Natural killer T cells constitutively expressing the interleukin-2 receptor α chain early in life are primed to respond to lower antigenic stimulation. Immunology 2010; 131: 289–299.
10. Skabytska Y, Kaesler S, Volz T, Biedermann T. The role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatments. Semin Immunopathol. 2016; 38: 29–43.
11. Two AM, Nakatsuji T, Kotol PF, Arvanitidou E, Du-Thumm L, Hata TR, et al. The Cutaneous Microbiome and Aspects of Skin Antimicrobial Defense System Resist Acute Treatment with Topical Skin Cleansers. J Invest Dermatol 2016; 136: 1950–1954.
12. Schommer NN, Gallo RL. Structure and function of the human skin microbiome. Trends Microbiol 2013; 21:660–668. Gallo RL, Hooper LV.Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol 2012; 12: 503–516.
13. Kuo I et al. The cutaneous innate immune response in patients with atopic dermatitisJ Allergy Clin Immunol 2013; 131: 266–278.
14. Kezic S, O’Regan GM, Lutter R, et al. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. J Allergy Clin Immunol. 2012; 129 (4): 1031–1039.e1.
15. Yoshida K, Kubo A, Fujita H, et al. Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis. J Allergy Clin Immunol. 2014; 134 (4): 856–864.
16. Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017; 139 (6): 1723–1734.
17. Demessant-Flavigny AL, et al. Skin microbiome dysbiosis and the role of Staphylococcus aureus in atopic dermatitis in adults and children: A narrative review. J Eur Acad Dermatol Venereol. 2023 Jun;37 Suppl 5:3–17. DOI: 10.1111/jdv.19125. PMID: 37232427.
18. Ogonowska P, et al. Colonization With Staphylococcus aureus in Atopic Dermatitis Patients: Attempts to Reveal the Unknown. Front Microbiol. 2021 Jan 11; 11: 567090. DOI: 10.3389/fmicb.2020.567090. PMID: 33505363; PMCID: PMC7830525.
19. Kim J, Kim BE, Ahn K, Leung DYM. Interactions Between Atopic Dermatitis and Staphylococcus aureus Infection: Clinical Implications. Allergy Asthma Immunol Res. 2019; 11 (5): 593–603. DOI: 10.4168/aair.2019.11.5.593
20. Joshi AA, Vocanson M, Nicolas JF, Wolf P, Patra V. Microbial derived antimicrobial peptides as potential therapeutics in atopic dermatitis. Front Immunol. 2023; 14: 1125635. Published 2023 Jan 25. DOI: 10.3389/fimmu.2023.1125635
21. Geoghegan, Joan A.; Irvine, Alan D.; Foster, Timothy J. . (2017). Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship. Trends in Microbiology, (), S0966842X17302573–. DOI: 10.1016/j.tim.2017.11.008
22. Papanikolaou M, Paul J, Nattkemper LA, Kirsner RS, Yosipovitch G. Prevalence and Mechanisms of Itch in Chronic Wounds: A Narrative Review. J Clin Med. 2025 Apr 22; 14 (9): 2877. DOI: 10.3390/jcm14092877. PMID: 40363908; PMCID: PMC 12072805.
23. Özdemіr E, Öksüz L. Effect of Staphylococcus aureus colonization and immune defects on the pathogenesis of atopic dermatitis. Arch Microbiol. 2024 Sep 20; 206 (10): 410. DOI: 10.1007/s00203–024–04134-w. PMID: 39302484.
24. Kline SN, Saito Y, Archer NK. Staphylococcus aureus Proteases: Orchestrators of Skin Inflammation. DNA Cell Biol. 2024 Oct; 43 (10): 483–491. DOI: 10.1089/dna.2024.0134. Epub 2024 Jul 3. PMID: 38957987; PMCID: PMC11535466.
25. Wong LS, Yen YT, Lee CH. The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis. Int J Mol Sci. 2021 Jul 5; 22 (13): 7227. DOI: 10.3390/ijms22137227. PMID: 34281281; PMCID: PMC8269281
26. Laccourreye O, Maisonneuve H. French scientific medical journals confronted by developments in medical writing and the transformation of the medical press. Eur Ann Otorhinolaryngol Head Neck Dis. 2019 Nov; 136 (6): 475–480. DOI: 10.1016/j.anorl.2019.09.002. Epub 2019 Sep 17. PMID: 31540851.
27. Tominaga M, Takamori K. Peripheral itch sensitization in atopic dermatitis. Allergol Int. 2022 Jul;71(3):265–277. DOI: 10.1016/j.alit.2022.04.003. Epub 2022 May 25. PMID: 35624035.
28. Gallo, R. L., & Horswill, A. R. (2024). Staphylococcus aureus: The Bug Behind the Itch in Atopic Dermatitis. In Journal of Investigative Dermatology (Vol. 144, Issue 5, pp. 950–953). Elsevier B.V. https://doi.org/10.1016/j.jid.2024.01.001.
29. Deng, L., et al. (2023). S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR 1 axis. Cell, 186 (24), 5375–5393.e25. https://doi.org/10.1016/j.cell.2023.10.019
30. Wollenberg A, et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol. 2022 Sep; 36 (9): 1409–1431. DOI: 10.1111/jdv.18345. PMID: 35980214.
31. Dumbuya H, et al. INDIVIDUAL ARTICLE: Atopic Dermatitis Skincare and Impact on Quality of Life for Patients with Skin of Color. J Drugs Dermatol. 2024 Mar 1; 23 (3): SF395747s6-SF395747s11. DOI: 10.36849/jdd.SF395747. PMID: 38443136.
32. Wollenberg A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018 Jun; 32 (6): 850–878. DOI: 10.1111/jdv.14888. PMID: 29878606.
33. Araviiskaia E, et al. The Role of a Novel Generation of Emollients, ’Emollients Plus’, in Atopic Dermatitis. Clin Cosmet Investig Dermatol. 2022; 15: 2705–2719.
34. Mahe et al. A novel Vitreoscilla filiformis extract grown in spa water-enriched media activates endogenous cutaneous antioxidant and antimicrobial defenses via the potent Toll-like receptor 2/protein kinase C zeta transduction pathway.New Clin Cosmet Investig Dermatol. 2013 30; 6: 191–6.
35. Gueniche et al. 2007.JEADV 22 (6): 746–747.
36. Gueniche et al. Br J Dermatol. 2008 Dec; 159 (6): 1357–63.
37. Augustin M, Langenbruch A, Blome C, et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020; 34 (1): 142–152.
38. Reza M. Namazi Nicotinamide as a potential addition to the anti-atopic dermatitis armamentarium. International Immunopharmacology 2004 June; 4 (6): 709–712.
39. Tanno O et al. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol, 143 (3), 525–531, 2000.
40. Zeichner and Seite. From Probiotic to Prebiotic Using Thermal Spring Water. 2018. JDD. 17 (6): 49–54.
Review
For citations:
Kruglova L.S., Araviyskaya E.A., Lvov A.N., Murashkin N.N., Sokolovsky E.V., Shatokhina E.A. Scientific and practical aspects and prospects for the use of emolent+ LIPIKAR BAUME AP+MAX® (resolution of the council of experts). Medical alphabet. 2026;(3):94-98. (In Russ.) https://doi.org/10.33667/2078-5631-2026-3-94-98
Views:
66
JATS XML
Email this article 